Clinical and therapeutic characterization of a Portuguese sample of patients with schizophrenia;Caracterización clínica y terapéutica de un muestreo portugués de paeientes con esquizofrenia

Actas Espanolas de Psiquiatria

Volumn 39, Issue 3, 2011, Pages 147-154

  Do Couto, Frederico Simões ^a,b   Queiroz, Cristina ^c   Barbosa, Teresa ^e   Ferreira, Luis ^g   Firmino, Horácio ^d   Viseu, Miguel ^f   Ramos, Luisa ^h   Romero, Jose ^h   Figueira, Maria Luisa ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b Institute de Farmacologia e Neurociências   (Portugal)

^c Bristol Meyers Squibb   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e Hospital Amato Lusitano   (Portugal)

^f Hospital São Pedro   (Portugal)

^g Centro Hospitalar e Universitário do Porto   (Portugal)

^h Centra Hospitalar Conde Ferreira   (Portugal)

Author keywords

Demography; Epidemiology; Portugal; Schizophrenia; Therapeutics

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PORTUGAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PORTUGAL; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79961052714     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bento A, Carreira M, Heitor MJ: Censo Psiquiátrico de 2001. Sintese dos Resultados Preliminares. Saúde em Números 2003;16(1):12.
2. Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: intergrating clinical and basic data. J Clin Psychiatry 1999;60(Suppl.8):21-8. (Pubitemid 29226622)
3. Baca Baldomero E, Leal Cercos C, Varela C, Riesgo Y, Roca M. Diagnostic process and management of schizophrenia in Spain: the ACEE project. Actas Esp Psiquiatr 2006;34(4):224-30. (Pubitemid 44196646)
4. Ashcroft DM, Frischer M, Lockett J, Chapman SR, Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf 2002;11(4):285-9. (Pubitemid 34704728)
5. Ruano D, Macedo A, Soares MJ, Valente J, Azevedo MH, Hutz MH, et al. Transthyretin: no association between serum levels or gene variants and schizophrenia. J Psychiatr Res 2007;41(8):667-72. (Pubitemid 46498104)
6. Diatta T, Blazejewski S, Portier A, Lignot S, Quesnot A, Moore N, et al. Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey. Fundam Clin Pharmacol 2007;21(4):371-8. (Pubitemid 47084024)
7. Soyka M, Albus M, Kathmann N, Finelli A, Hofstetter S, Holzbach R, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci 1993;242(6):362-72. (Pubitemid 23225617)
8. Rodriguez-Jimenez R, Aragiies M, Jimenez-Arriero MA, Ponce G, Mufioz A, Bagney A, et al. Dual diagnosis in psychiatric inpatients: prevalence and general characteristics. Invest Clin 2008;49(2):195-205.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12):1209-23.
10. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006;67(4):575-83. (Pubitemid 43764234)
11. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia research 2008; 10:(1-3):273-86.
12. Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. The Medical journal of Australia. 2003;178 Suppl:S67-70. (Pubitemid 36591938)
13. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 1996;169(4):444-50.
14. Perkins DO, Gu H, Weiden PJ, McEnvoy JP, Hamer RM, Lierbermen JA. On behalf of the Comparison of Atypicals in First Episode Study Group. Predictors of treatment discontinuation and nonadherence in patients recovering from first episode of schizophrenia, schizophreniform disorder or schizoaffective disorders; a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2007: e1-e8.
15. Bitter I, Treuer T, Dyachkova Y, Martenyi F, McBride M, Ungvari GS. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Neuropsychopharmacoly 2008;18{3): 170-80.
16. National Institute of Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Health Technology Appraisal No. 43. 2002. http://www.nice.org.uk.
17. Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008;69(2):240.
18. Bret P, Bonnet F, Bret MC, Jaffre A. Etude des pratiques de prescription des neuroleptiques dits "atyipics" ou antipsychotics atypics au centre hospitaler de Charles Perrens de Bordeuaux, Encephale 2002;27:329-42.